Impact Factor
3.77
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.26
5,821 total citations
h5-index
90
h5 depth signal
Cited share
40.1%
746 of 1,861
Total citations
5,821
Citation footprint
Metric signal
3.44
External metric anchor
Self-citation
2.2%
130 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,529
France
1,411
Germany
1,234
United Kingdom
1,176
Italy
1,173
Citing Fields of Research
Oncology
3,720
Breast Cancer
2,243
Immunology
1,675
Cancer & Development
1,312
Lung Cancer
891
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
41,517
Articles tracked across the journal lifetime
Indexed publication set
1,861
746 cited publications
Last 12 months
969
80.8 publications/month
Open access share
24.1%
234 OA publications in the last year
Leading citing country
United States
1,529 citing publications
Leading citing field
Oncology
3,720 citing publications
Latest tracked publication
18 October 2026
10 recent records available
Coverage & Indexing History
v26n1, Jan. 1990-
v26n1, Jan. 1990-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Breast Cancer
Lymphomas
Immunology
Lung Cancer
Issuing & Sponsoring Bodies
Contributor
European Organization for Research on Treatment of Cancer
Contributor
European Association for Cancer Research
Broad Categories
Neoplasms
Breast Cancer
Lymphomas
Immunology
Lung Cancer
Liver & Colon Cancer
Cancer, Autophagy & Apoptosis
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.ejca.2026.117790
Open DOI
A new era in anti-RAS therapy: unique challenges and opportunities for radiotherapy clinical trials
02
03
DOI 10.1016/j.ejca.2026.117780
Open DOI
Outcomes of CD20-targeting CAR T-cell therapy in patients with advanced melanoma: MB-CART20.1 Melanoma phase I trial
04
05
06
07
08
DOI 10.1016/j.ejca.2026.117782
Open DOI
What does addressing cancer inequalities really mean? Five principles that can drive global action
09
10
DOI 10.1016/j.ejca.2026.117783
Open DOI
The APA Score Stratifies Prognosis in Patients with hepatocellular carcinoma Treated with Atezolizumab-Bevacizumab
Bibliographical & Catalog Notes
Issues for Apr./May 1992-v. 28A, no. 6/7 also called: European journal of cancer. Part A.
Monthly.
Title from cover.
Chronological designation dropped with v. 28A, no. 8/9.
Also issued online.
Vol. 26, no. 1 (JAN 1990)19900410 Notice published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper